NASDAQ:AFMD Affimed Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. $2.93 +0.12 (+4.27%) (As of 07/5/2022 11:39 AM ET) Add Compare Share Today's Range$2.76▼$2.9550-Day Range$2.27▼$4.0652-Week Range$2.23▼$7.65Volume21,640 shsAverage Volume1.18 million shsMarket Capitalization$361.62 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Affimed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside241.3% Upside$10.00 Price TargetShort InterestHealthy3.22% of Shares Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.40Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.72) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.06 out of 5 starsMedical Sector446th out of 1,428 stocksPharmaceutical Preparations Industry206th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Affimed has a forecasted upside of 241.3% from its current price of $2.93.Amount of Analyst CoverageAffimed has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.22% of the outstanding shares of Affimed have been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently decreased by 2.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 2.4 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Affimed this week, compared to 3 articles on an average week.Search Interest7 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by Institutions63.47% of the stock of Affimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to decrease in the coming year, from ($0.72) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address About Affimed (NASDAQ:AFMD) StockAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Stock News HeadlinesJune 30, 2022 | globenewswire.comAffimed Establishes Scientific Advisory Board - GlobeNewswireJune 29, 2022 | seekingalpha.comAffimed Stock: Preparing For Key Inflection Points (NASDAQ:AFMD) - Seeking AlphaJune 23, 2022 | benzinga.comSVB Leerink Maintains Outperform on Affimed, Lowers Price Target to $9 - Benzinga - BenzingaJune 12, 2022 | streetinsider.comAffimed (AFMD) Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association - StreetInsider.comJune 2, 2022 | nasdaq.comAFMD To Report REDIRECT Data In Q4, VEEV Boosts EPS & Revenue Outlook, MESO At Work - NasdaqJune 1, 2022 | seekingalpha.comAffimed GAAP EPS of -€0.14, revenue of €8.02M - Seeking AlphaJune 1, 2022 | globenewswire.comAffimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress - GlobeNewswireMay 31, 2022 | nasdaq.comPre-Market Earnings Report for June 1, 2022 : CPRI, DCI, WB, AFMD, CONN - NasdaqMay 31, 2022 | seekingalpha.comAffimed Q1 2022 Earnings Preview (NASDAQ:AFMD) - Seeking AlphaMay 26, 2022 | globenewswire.comAffimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO) - GlobeNewswireMay 26, 2022 | finance.yahoo.comAffimed to Present at the 2022 Jefferies Healthcare ConferenceMay 25, 2022 | finance.yahoo.comAffimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 24, 2022 | benzinga.comAffimed Announces Annual General Meeting of Shareholders - BenzingaMay 24, 2022 | finance.yahoo.comAffimed Announces Annual General Meeting of ShareholdersMay 24, 2022 | finance.yahoo.comAffimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022May 17, 2022 | finance.yahoo.comAffimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity - Yahoo FinanceMay 16, 2022 | globenewswire.comAffimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity - GlobeNewswireMay 16, 2022 | finance.yahoo.comAffimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural ImmunityMay 14, 2022 | finance.yahoo.comWhat Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own?May 12, 2022 | globenewswire.comAffimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - GlobeNewswireMay 9, 2022 | nasdaq.com3 Small-Caps That Might Be Acquisition Candidates - NasdaqMay 8, 2022 | finance.yahoo.comAffimed Provides Update on ASCO AFM13-104 Oral Presentation - Yahoo FinanceMay 6, 2022 | benzinga.comAffimed Reports American Society Of Clinical Oncology Informed Co.'s Collaborator For AFM13-104 It Remove - BenzingaMay 6, 2022 | benzinga.comUPDATE: Affimed Says Removal Of Presentation At American Society Of Clinical Oncology Not Related To Stat - BenzingaMay 6, 2022 | globenewswire.comAffimed Provides Update on ASCO AFM13-104 Oral Presentation - GlobeNewswireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees197Year FoundedN/ACompany Calendar Last Earnings6/01/2022Today7/05/2022Next Earnings (Estimated)9/14/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+241.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,060,000.00 Net Margins-215.31% Pretax Margin-207.09% Return on Equity-58.18% Return on Assets-35.31% Debt Debt-to-Equity Ratio0.13 Current Ratio3.13 Quick Ratio3.12 Sales & Book Value Annual Sales$47.76 million Price / Sales7.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book2.25Miscellaneous Outstanding Shares123,420,000Free FloatN/AMarket Cap$361.62 million OptionableOptionable Beta2.45 Affimed Frequently Asked Questions Should I buy or sell Affimed stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Affimed stock. View analyst ratings for Affimed or view top-rated stocks. What is Affimed's stock price forecast for 2022? 6 Wall Street analysts have issued 1 year target prices for Affimed's stock. Their AFMD stock forecasts range from $7.00 to $12.00. On average, they expect Affimed's share price to reach $10.00 in the next year. This suggests a possible upside of 241.3% from the stock's current price. View analysts' price targets for Affimed or view top-rated stocks among Wall Street analysts. How has Affimed's stock performed in 2022? Affimed's stock was trading at $5.52 on January 1st, 2022. Since then, AFMD stock has decreased by 46.9% and is now trading at $2.93. View the best growth stocks for 2022 here. When is Affimed's next earnings date? Affimed is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022. View our earnings forecast for Affimed. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, June, 1st. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $8.98 million during the quarter, compared to analyst estimates of $9.93 million. Affimed had a negative net margin of 215.31% and a negative trailing twelve-month return on equity of 58.18%. During the same quarter last year, the firm earned $0.01 earnings per share. View Affimed's earnings history. Who are Affimed's key executives? Affimed's management team includes the following people: Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 61, Pay $821.42k)Mr. Angus W. Smith, CFO & Member of Management Board (Age 40, Pay $591.67k)Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 58, Pay $647.28k)Ms. Denise Mueller, Chief Bus. Officer & Member of Management Board (Age 53, Pay $564.4k)Dr. Andreas Harstrick M.D., Chief Medical Officer & Member of Management Board (Age 61, Pay $537.12k)Dr. Arndt J. G. Schottelius M.D., Ph.D., Chief Scientific Officer & Member of Management Board (Age 56, Pay $649.37k)Prof. Melvyn Little, Founder & ConsultantMr. Michael Wolf, Head of Fin. & Admin. (Age 55)Mr. Alexander Fudukidis, Head of Investor RelationsDr. Uwe Reusch, Head of Cell Culture Who are some of Affimed's key competitors? Some companies that are related to Affimed include Day One Biopharmaceuticals (DAWN), Zentalis Pharmaceuticals (ZNTL), Taro Pharmaceutical Industries (TARO), Sierra Oncology (SRRA), Prothena (PRTA), Madrigal Pharmaceuticals (MDGL), Agios Pharmaceuticals (AGIO), Amylyx Pharmaceuticals (AMLX), Myovant Sciences (MYOV), Kura Oncology (KURA), Reata Pharmaceuticals (RETA), 23andMe (ME), Syndax Pharmaceuticals (SNDX), IVERIC bio (ISEE) and Arcutis Biotherapeutics (ARQT). View all of AFMD's competitors. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). What is Affimed's stock symbol? Affimed trades on the NASDAQ under the ticker symbol "AFMD." How do I buy shares of Affimed? Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Affimed's stock price today? One share of AFMD stock can currently be purchased for approximately $2.93. How much money does Affimed make? Affimed (NASDAQ:AFMD) has a market capitalization of $361.62 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How many employees does Affimed have? Affimed employs 197 workers across the globe. How can I contact Affimed? Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for Affimed is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777. This page (NASDAQ:AFMD) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
